Original Research
Published on 19 Feb 2026
Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis
in Health Economics
- 100 views
Original Research
Published on 19 Feb 2026
in Health Economics
Original Research
Accepted on 17 Feb 2026
in Health Economics
Original Research
Published on 17 Feb 2026
in Health Economics
Original Research
Published on 17 Feb 2026
in Health Economics
Systematic Review
Published on 17 Feb 2026
in Health Economics
Original Research
Published on 17 Feb 2026
in Health Economics
Data Report
Accepted on 16 Feb 2026
in Health Economics
Original Research
Accepted on 16 Feb 2026
in Health Economics
Original Research
Accepted on 16 Feb 2026
in Health Economics
Original Research
Accepted on 16 Feb 2026
in Health Economics
Original Research
Published on 13 Feb 2026
in Health Economics
Original Research
Published on 13 Feb 2026
in Health Economics
Original Research
Accepted on 12 Feb 2026
in Health Economics
Original Research
Accepted on 12 Feb 2026
in Health Economics
Original Research
Accepted on 12 Feb 2026
in Health Economics
Original Research
Published on 12 Feb 2026
in Health Economics
Data Report
Published on 10 Feb 2026
in Health Economics
Systematic Review
Published on 09 Feb 2026
in Health Economics
Original Research
Published on 09 Feb 2026
in Health Economics
Original Research
Published on 06 Feb 2026
in Health Economics
Original Research
Accepted on 05 Feb 2026
in Health Economics
Original Research
Published on 05 Feb 2026
in Health Economics
Original Research
Published on 05 Feb 2026
in Health Economics
Original Research
Published on 05 Feb 2026
in Health Economics